- Home
- FHTX vs GLRE Comparison
FHTX vs GLRE Comparison
Compare FHTX & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- GLRE
- Stock Information
- Founded
- FHTX 2015
- GLRE 2004
- Country
- FHTX United States
- GLRE Cayman Islands
- Employees
- FHTX N/A
- GLRE N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- GLRE Property-Casualty Insurers
- Sector
- FHTX Health Care
- GLRE Finance
- Exchange
- FHTX Nasdaq
- GLRE Nasdaq
- Market Cap
- FHTX 513.7M
- GLRE 471.2M
- IPO Year
- FHTX 2020
- GLRE 2007
- Fundamental
- Price
- FHTX $9.04
- GLRE $14.78
- Analyst Decision
- FHTX Strong Buy
- GLRE
- Analyst Count
- FHTX 5
- GLRE 0
- Target Price
- FHTX $16.00
- GLRE N/A
- AVG Volume (30 Days)
- FHTX 123.1K
- GLRE 77.3K
- Earning Date
- FHTX 11-04-2024
- GLRE 11-04-2024
- Dividend Yield
- FHTX N/A
- GLRE N/A
- EPS Growth
- FHTX N/A
- GLRE N/A
- EPS
- FHTX N/A
- GLRE 2.53
- Revenue
- FHTX $25,515,000.00
- GLRE $702,254,000.00
- Revenue This Year
- FHTX N/A
- GLRE N/A
- Revenue Next Year
- FHTX $15.40
- GLRE N/A
- P/E Ratio
- FHTX N/A
- GLRE $6.12
- Revenue Growth
- FHTX N/A
- GLRE 8.96
- 52 Week Low
- FHTX $2.70
- GLRE $10.49
- 52 Week High
- FHTX $10.25
- GLRE $15.82
- Technical
- Relative Strength Index (RSI)
- FHTX 61.38
- GLRE 63.70
- Support Level
- FHTX $7.95
- GLRE $13.13
- Resistance Level
- FHTX $9.54
- GLRE $15.82
- Average True Range (ATR)
- FHTX 0.56
- GLRE 0.38
- MACD
- FHTX 0.19
- GLRE 0.18
- Stochastic Oscillator
- FHTX 82.08
- GLRE 61.34
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed, and income from investments.